細胞株開発の市場規模、シェア、動向分析レポート：製品・サービス別、原料別、細胞株タイプ別、用途別、セグメント予測、2023年～2030年

細胞株開発市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の細胞株開発市場規模は2030年までに100億9,000万米ドルに達し、2023年から2030年までのCAGRは9.81％で拡大すると予測されています。

細胞株開発（CLD）市場の拡大を促す主な要因の1つは、特にコロナウイルスの蔓延後、世界中でワクチン生産が増加していることです。新しいヘルスケア技術の利用が増加し、がん罹患率が上昇することで、CLD市場にはより魅力的で有利な成長見通しが生まれています。生物製剤分野の拡大と成長もまた、CLD市場開拓の主要な決定要因となると思われます。

技術的に改良されたCLD治療薬の上市が増加していることも、市場拡大の原動力となると思われます。例えば、BICOの子会社であるCYTENAは、2021年10月に、完全に自動化された安定した細胞株開発のための新しいプラットフォームを発表しました。費用対効果が高く、より優れたラボの自動化を可能にするため、このシステムはCYTENAのクラス最高のリキッドハンドリング情報と、既存の確立された単一細胞分注技術を統合しています。BICOのバイオ・コンバージェンス・アジェンダは、抗体治療、遺伝子治療、バイオシミラー製造などの次世代医療サービスの発展へのアクセス可能性の拡大を通じて推進されます。

さらに、2021年7月のPharma Manufacturing Updatesによると、ノバルティスのEntrestoとバイオジェンのSpinrazaを含むいくつかのブロックバスターを含む約20の医薬品が2023年に特許満了を迎える予定です。先発医薬品の特許切れは、バイオシミラーの誕生をもたらしました。その結果、細胞株開発の必要性が高まっています。したがって、市場成長の原動力となると思われます。

さらに、提携、拡大、買収などの企業戦略の成長も市場成長の原動力となっています。例えば、ProBioGenとGranite Bioは2022年7月、GMP製造＆細胞株開発ソリューションを提供し、Granite BioのmAbパイプライン開発をサポートするために提携しました。同様に、2022年6月、富士フイルム株式会社は、FUJIFILM Diosynth Biotechnologiesの細胞培養生産能力を改善・拡大するために16億米ドルを投資すると発表しました。さらに、2022年10月、Cytiva社は、先進的なCLDとウイルスベクター製造技術の著名なドイツメーカーであるCEVEC Pharmaceuticals社を買収しました。この開発を通じて、CEVECはCytivaがバイオ製造技術におけるリーダー的地位を維持するのに役立つと思われます。

しかし、研究開発能力を構築するために必要な高額な資本費用と支出は、細胞株開発産業の障壁となると思われます。

細胞株開発市場レポートハイライト

• 製品別では、試薬・培地セグメントが2022年に43.78%の最大シェアを占めました。コスト集約的な性質と生物製剤の製造における頻繁な使用により、これらの品目は最大の収益シェアを占めています。
• その急速な拡大は、哺乳類細胞株がヒトと同一の複雑なタンパク質を発現することができるため、哺乳類細胞株によるバイオ医薬品の効果的な製造の結果です。
• 細胞株タイプ別では、組換え細胞株企業セグメントが2022年に31.79％の最大シェアを占めました。これは、生物製剤製造プロセス、遺伝子活性化、タンパク質相互作用などに広く応用されているためです。
• 用途別では、生物生産分野が2022年に46.30%の最大シェアを占めました。体外研究活動の増加、製品の安全性と有効性への懸念、バイオシミラーへの需要、細胞治療への需要の高まりなどの要因が、バイオ生産産業を牽引しています。
• 北米が2022年に39.22%と大きなシェアを占めたのは、絶え間ない技術改良の存在とそれに続く新しい発見が、バイオ生産のための新しいプロセスの採用に火をつけたからです。Thermo Fisher Scientific Inc.、Sigma-Aldrich Corporation、American Type Culture Collection（ATCC）など、高品質なCLDサービスを提供するこの地域の研究企業による厳格な活動が成長に寄与しています。
• 同市場の主要プレーヤーには、Thermo Fisher Scientific Inc.、Corning Inc.、Lonza、Creative BioLabs.、WuXi PharmaTech、Sartorius AG、Merck KGaA、Advanced Instruments、Berkeley Lights、Danaherなどがあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場動向と展望
• 市場力学
  • 大ヒット生物製剤の特許満了
  • モノクローナル抗体の需要の高まり
  • ワクチン生産量の増加
  • 細胞株開発の技術進歩
  • がんの罹患率の増加
  • バイオテクノロジー分野での研究開発投資の増加
• 市場抑制要因分析
  • 複雑な規制枠組みの存在
• 事業環境分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 製品・サービス別ビジネス分析

• 世界の細胞株開発市場：製品とサービスの変動分析
• 試薬と培地
• 装置
  • 自動化システム
  • 遠心分離機
  • バイオリアクター
  • 保管設備
  • その他
• 付属品と消耗品
• サービス

第5章 ソース別ビジネス分析

• 世界の細胞株開発市場：ソース変動分析
• 哺乳類細胞株
• 非哺乳類細胞株

第6章 細胞株タイプ別ビジネス分析

• 世界の細胞株開発市場：細胞株の種類の変動分析
• 組換え細胞株
• ハイブリドーマ
• 連続細胞株
• 初代細胞株

第7章 用途別ビジネス分析

• 世界の細胞株開発市場：用途別変動分析
• 生物生産
• 創薬
• 毒性試験
• 組織工学
• その他

第8章 地域別ビジネス分析

• 世界の細胞株開発市場の地域別シェア、2022年および2030年
• 北米
  • 北米細胞株開発市場、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州細胞株開発市場、2018～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • アジア太平洋の細胞株開発市場、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカの細胞株開発市場、2018～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • MEA細胞株開発市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 企業の分類
• 戦略マッピング
• Company Market/PositionShare Analysis, 2022
• 企業プロファイル・一覧表
  • Thermo Fisher Scientific Inc.
  • Danaher
  • Merck KGaA
  • Sartorius AG
  • Lonza
  • WuXi PharmaTech
  • Advanced Instruments
  • Berkeley Lights
  • Creative BioLabs
  • Corning Inc.

List of Tables

• Table 1 List Of Secondary Sources
• Table 2 List Of Abbreviations
• Table 3 Global Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 4 Global Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 5 Global Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 6 Global Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 7 North America Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 8 North America Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 9 North America Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 10 North America Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 11 North America Cell line development market by Country, 2018 - 2030 (USD Million)
• Table 12 U.S. Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 13 U.S. Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 14 U.S. Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 15 U.S. Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 16 Canada Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 17 Canada Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 18 Canada Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 19 Canada Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 20 Europe Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 21 Europe Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 22 Europe Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 23 Europe Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 24 Europe Cell line development market by Country, 2018 - 2030 (USD Million)
• Table 25 UK Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 26 UK Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 27 UK Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 28 UK Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 29 Germany Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 30 Germany Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 31 Germany Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 32 Germany Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 33 France Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 34 France Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 35 France Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 36 France Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 37 Italy Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 38 Italy Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 39 Italy Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 40 Italy Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 41 Spain Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 42 Spain Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 43 Spain Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 44 Spain Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 45 Denmark Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 46 Denmark Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 47 Denmark Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 48 Denmark Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 49 Sweden Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 50 Sweden Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 51 Sweden Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 52 Sweden Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 53 Norway Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 54 Norway Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 55 Norway Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 56 Norway Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific Cell line development market by Country, 2018 - 2030 (USD Million)
• Table 62 China Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 63 China Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 64 China Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 65 China Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 66 Japan Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 67 Japan Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 68 Japan Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 69 Japan Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 70 India Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 71 India Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 72 India Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 73 India Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 74 South Korea Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 75 South Korea Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 76 South Korea Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 77 South Korea Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 78 Australia Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 79 Australia Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 80 Australia Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 81 Australia Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 82 Thailand Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 83 Thailand Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 84 Thailand Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 85 Thailand Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 86 Latin America Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 87 Latin America Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 88 Latin America Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 89 Latin America Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 90 Latin America Cell line development market by Country, 2018 - 2030 (USD Million)
• Table 91 Brazil Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 92 Brazil Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 93 Brazil Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 94 Brazil Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 95 Mexico Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 96 Mexico Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 97 Mexico Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 98 Mexico Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 99 Argentina Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 100 Argentina Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 101 Argentina Cell line development market by Type of Cell Liner, 2018 - 2030 (USD Million)
• Table 102 Argentina Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 103 Middle East & Africa Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Cell line development market by Country, 2018 - 2030 (USD Million)
• Table 108 South Africa Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 109 South Africa Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 110 South Africa Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 111 South Africa Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 116 UAE Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 117 UAE Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 118 UAE Cell line development market by Type of Cell Line, 2018 - 2030 (USD Million)
• Table 119 UAE Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 120 Kuwait Cell line development market by Product & Services, 2018 - 2030 (USD Million)
• Table 121 Kuwait Cell line development market by Source, 2018 - 2030 (USD Million)
• Table 122 Kuwait Cell line development market By Type of Cell Line, 2018 - 2030 (USD Million)
• Table 123 Kuwait Cell line development market by Application, 2018 - 2030 (USD Million)
• Table 124 Participant's Overview
• Table 125 Financial Performance
• Table 126 Key Companies Undergoing Expansions
• Table 127 Key Companies Undergoing Acquisitions
• Table 128 Key Companies Undergoing Collaborations
• Table 129 Key Companies Launching New Products/Services
• Table 130 Key Companies Undergoing Partnerships
• Table 131 Key Companies Undertaking Other Strategies

List of Figures

• Fig. 1 Market Others process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary Others pattern
• Fig. 4 Market Others approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market summary, 2022 (USD Million)
• Fig. 9 Market segmentation & scope
• Fig. 10 Market driver impact
• Fig. 11 Market restraint impact
• Fig. 12 Penetration & growth prospect mapping
• Fig. 13 Porter's analysis
• Fig. 14 SWOT analysis
• Fig. 15 Global cell line development market: Product & services outlook and key takeaways
• Fig. 16 Global cell line development market: Product & services movement analysis
• Fig. 17 Global reagents and media market, 2018 - 2030 (USD Million)
• Fig. 18 Global equipment market, 2018 - 2030 (USD Million)
• Fig. 19 Global Automated Systems market, 2018 - 2030 (USD Million)
• Fig. 20 Global centrifuges market, 2018 - 2030 (USD Million)
• Fig. 21 Global bioreactors market, 2018 - 2030 (USD Million)
• Fig. 22 Global storage equipment market, 2018 - 2030 (USD Million)
• Fig. 23 Global Others market, 2018 - 2030 (USD Million)
• Fig. 24 Global Accessories and consumables market, 2018 - 2030 (USD Million)
• Fig. 25 Global cell line development market: Source outlook and key takeaways
• Fig. 26 Global cell line development market: Source movement analysis
• Fig. 27 Global mammalian cell line market, 2018 - 2030 (USD Million)
• Fig. 28 Global non-mammalian cell line market, 2018 - 2030 (USD Million)
• Fig. 29 Global insects market, 2018 - 2030 (USD Million)
• Fig. 30 Global amphibians market, 2018 - 2030 (USD Million)
• Fig. 31 Global cell line development market: Type of cell line outlook and key takeaways
• Fig. 32 Global cell line development market: Type of cell line movement analysis
• Fig. 33 Global recombinant cell lines market, 2018 - 2030 (USD Million)
• Fig. 34 Global hybridomas market, 2018 - 2030 (USD Million)
• Fig. 35 Global continuous cell lines market, 2018 - 2030 (USD Million)
• Fig. 36 Global primary cell lines market, 2018 - 2030 (USD Million)
• Fig. 37 Global cell line development market: Application outlook and key takeaways
• Fig. 38 Global cell line development market: Application movement analysis
• Fig. 39 Global bioproduction market, 2018 - 2030 (USD Million)
• Fig. 40 Global drug discovery market, 2018 - 2030 (USD Million)
• Fig. 41 Global toxicity testing market, 2018 - 2030 (USD Million)
• Fig. 42 Global tissue engineering market, 2018 - 2030 (USD Million)
• Fig. 43 Global Others market, 2018 - 2030 (USD Million)
• Fig. 44 Global cell line development market: Regional outlook and key takeaways
• Fig. 45 North America cell line development market, 2018 - 2030 (USD Million)
• Fig. 46 U.S. key country dynamics
• Fig. 47 U.S. cell line development market, 2018 - 2030 (USD Million)
• Fig. 48 Canada key country dynamics
• Fig. 49 Canada cell line development market, 2018 - 2030 (USD Million)
• Fig. 50 Europe cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Germany key country dynamics
• Fig. 52 Germany cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 France key country dynamics
• Fig. 54 France cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 UK key country dynamics
• Fig. 56 UK cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Italy key country dynamics
• Fig. 58 Italy cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Spain key country dynamics
• Fig. 60 Spain cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 Denmark key country dynamics
• Fig. 62 Denmark cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 Sweden key country dynamics
• Fig. 64 Sweden cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 Norway key country dynamics
• Fig. 66 Norway cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 Asia-Pacific cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 68 China key country dynamics
• Fig. 69 China cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 India key country dynamics
• Fig. 71 India cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 72 South Korea key country dynamics
• Fig. 73 South Korea cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 Japan key country dynamics
• Fig. 75 Japan cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 76 Australia key country dynamics
• Fig. 77 Australia cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 78 Thailand key country dynamics
• Fig. 79 Thailand cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 80 Latin America cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 Brazil key country dynamics
• Fig. 82 Brazil cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 83 Mexico key country dynamics
• Fig. 84 Mexico cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 85 Argentina key country dynamics
• Fig. 86 Argentina cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 87 MEA cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 88 South Africa key country dynamics
• Fig. 89 South Africa cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 90 Saudi Arabia key country dynamics
• Fig. 91 Saudi Arabia cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 92 UAE key country dynamics
• Fig. 93 UAE cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 94 Kuwait key country dynamics
• Fig. 95 Kuwait cell line development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 96 Market participant categorization
• Fig. 97 Cell line development market share analysis, 2022
• Fig. 98 Strategy framework

Cell Line Development Market Growth & Trends:

The global cell line development market size is expected to reach USD 10.09 billion by 2030 and is expected to expand at a CAGR of 9.81% from 2023 to 2030, according to a new report by Grand View Research, Inc.. One of the primary factors driving the expansion of the cell line development (CLD) market is an increase in vaccine production around the world, especially after the spread of coronavirus. Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market. The expansion and growth of the biologics sector will also be a major CLD market development determinant.

The increasing product launches of technologically improved products for CLD are likely to drive market expansion. For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021. To enable cost-effective and better laboratory automation, the system integrates CYTENA's best-in-class liquid handling information with its existing established single-cell dispensing technology. BICO's Bio Convergence agenda is advanced through the broadening of accessibility to the advancement of next-generation medical services such as antibody treatments, gene therapies, and biosimilar production.

Moreover, according to the July 2021 Pharma Manufacturing Updates, approximately 20 drugs, comprising a few blockbusters including Novartis' Entresto & Biogen's Spinraza, are going to have their patents scheduled to expire in 2023. The expiration of branded pharmaceuticals has resulted in the creation of biosimilars. As a result, the requirement for cell line development is increasing. Thus, it will drive the market growth.

Furthermore, the growing company strategies such as collaboration, expansion, and acquisitions are also driving the market growth. For instance, ProBioGen and Granite Bio collaborated in July 2022 to provide GMP manufacturing & cell line development solutions and support Granite Bio's mAb pipeline development. Similarly, in June 2022, FUJIFILM Corporation announced a USD 1.6 billion investment to improve and expand the cell culture production capabilities of FUJIFILM Diosynth Biotechnologies. Furthermore, in October 2022, Cytiva, acquired CEVEC Pharmaceuticals, a prominent German producer of advanced CLD & viral vector manufacturing technology. Through this development, CEVEC will help Cytiva maintain its leadership position in biomanufacturing technologies.

However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.

Cell Line Development Market Report Highlights:

• By product, the reagents and media segment accounted for the largest share of 43.78% in 2022. Due to their cost-intensive nature and frequent use in the manufacturing of biologics, these items account for the biggest revenue share.
• By source, the mammalian cell line segment accounted for the largest share of 72.62% in 2022.Its rapid expansion is a result of the effective manufacture of biopharmaceuticals by mammalian cell lines, as they are able to express complex proteins that are identical to those found in humans.
• By type of cell line, the recombinant cell lines companies segment accounted for the largest share of 31.79% in 2022 due to its widespread application in biologics manufacturing processes, gene activation, including protein interactions.
• By application, the bioproduction segment held the largest market share of 46.30% in 2022. Factors such as increased in-vitro research activities, product safety and efficacy concerns, the demand for biosimilars, and rising demand for cellular therapies are driving the bioproduction industry.
• North America held the larger share of 39.22% in 2022 due to the presence of constant technological improvements followed by new discoveries sparking the adoption of newer processes for bioproduction. The presence of rigorous activities carried out by research businesses operating in this region, such as Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation, and American Type Culture Collection (ATCC), which provide high-quality CLD services, is contributing to growth.
• A few of the key market players of the market include Thermo Fisher Scientific Inc., Corning Inc., Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius AG, Merck KGaA, Advanced Instruments, Berkeley Lights, Danaher among others.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Information analysis
  • 1.2.2. Market formulation & data visualization
  • 1.2.3. Data validation & publishing
• 1.3. Information Procurement
  • 1.3.1. Primary Others
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Market Model
• 1.7. Objectives
  • 1.7.1. Objective 1
  • 1.7.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Patent expiration of blockbuster biologics
  • 3.3.2. Rising demand for monoclonal antibodies
  • 3.3.3. Increasing vaccine production
  • 3.3.4. Technological advancement for the cell line development
  • 3.3.5. Increasing prevalence of cancer
  • 3.3.6. Growing R&D investments in biotechnology sector
• 3.4. Market Restraint Analysis
  • 3.4.1. Presence of complicated regulatory framework
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product & Services Business Analysis

• 4.1. Global cell line development market: Product & Services Movement Analysis
• 4.2. Reagents and media
  • 4.2.1. Reagents and media Market, 2018 - 2030 (USD Million)
• 4.3. Equipment
  • 4.3.1. Equipment Market, 2018 - 2030 (USD Million)
  • 4.3.2. Automated Systems
    • 4.3.2.1. Automated Systems Market, 2018 - 2030 (USD Million)
  • 4.3.3. Centrifuges
    • 4.3.3.1. Centrifuges Market, 2018 - 2030 (USD Million)
  • 4.3.4. Bioreactors
    • 4.3.4.1. Bioreactors Market, 2018 - 2030 (USD Million)
  • 4.3.5. Storage equipment
    • 4.3.5.1. Storage equipment Market, 2018 - 2030 (USD Million)
  • 4.3.6. Others
    • 4.3.6.1. Others Market, 2018 - 2030 (USD Million)
• 4.4. Accessories and consumables
  • 4.4.1. Accessories and consumables Market, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Source Business Analysis

• 5.1. Global cell line development market: Source Movement Analysis
• 5.2. Mammalian cell line
  • 5.2.1. Mammalian cell line Market, 2018 - 2030 (USD Million)
• 5.3. Non-mammalian cell line
  • 5.3.1. Non-mammalian cell line Market, 2018 - 2030 (USD Million)
  • 5.3.2. Insects
    • 5.3.2.1. Insects Market, 2018 - 2030 (USD Million)
  • 5.3.3. Amphibians
    • 5.3.3.1. Amphibians Market, 2018 - 2030 (USD Million)

Chapter 6. Type of Cell Lines Business Analysis

• 6.1. Global cell line development market: Type of Cell Lines Movement Analysis
• 6.2. Recombinant cell lines
  • 6.2.1. Recombinant cell lines Market, 2018 - 2030 (USD Million)
• 6.3. Hybridomas
  • 6.3.1. Hybridomas Market, 2018 - 2030 (USD Million)
• 6.4. Continuous cell lines
  • 6.4.1. Continuous cell lines Market, 2018 - 2030 (USD Million)
• 6.5. Primary cell lines
  • 6.5.1. Primary cell lines Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Global cell line development market: Application Movement Analysis
• 7.2. Bioproduction
  • 7.2.1. Bioproduction Market, 2018 - 2030 (USD Million)
• 7.3. Drug discovery
  • 7.3.1. Drug discovery Market, 2018 - 2030 (USD Million)
• 7.4. Toxicity testing
  • 7.4.1. Toxicity testing Market, 2018 - 2030 (USD Million)
• 7.5. Tissue engineering
  • 7.5.1. Tissue engineering Market, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Global Cell line development market Share By Region, 2022 & 2030
• 8.2. North America
  • 8.2.1. North America cell line development market, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. U.S. cell line development market, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Canada cell line development market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Cell line development market, 2018 - 2030 (USD Million)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. Germany cell line development market, 2018 - 2030 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. UK cell line development market, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. France cell line development market, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Italy cell line development market, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. Spain cell line development market, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Denmark cell line development market, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Target Disease Prevalence
    • 8.3.8.5. Sweden cell line development market, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Target Disease Prevalence
    • 8.3.9.5. Norway cell line development market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific cell line development market, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Japan cell line development market, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. China cell line development market, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. India cell line development market, 2018 - 2030 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. South Korea cell line development market, 2018 - 2030 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Australia cell line development market, 2018 - 2030 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. Thailand cell line development market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America cell line development market, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Brazil cell line development market, 2018 - 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Mexico cell line development market, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. Argentina cell line development market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA cell line development market, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. South Africa cell line development market, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Saudi Arabia cell line development market, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Target Disease Prevalence
    • 8.6.4.5. UAE cell line development market, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Target Disease Prevalence
    • 8.6.5.5. Kuwait cell line development market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market/PositionShare Analysis, 2022
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Danaher
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Merck KGaA
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Sartorius AG
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Lonza
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. WuXi PharmaTech
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Advanced Instruments
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Berkeley Lights
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Creative BioLabs
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Corning Inc.
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives